Lineage Cell Therapeutics (LCTX) Revenue (2010 - 2026)

Lineage Cell Therapeutics' Revenue history runs 17 years deep, the most recent figure standing at $1.7 million for Q1 2026.

• In Q1 2026, Revenue rose 14.85% year-over-year to $1.7 million; the TTM figure through Mar 2026 stood at $14.8 million (up 54.64% YoY), while the FY2025 annual figure was $14.6 million, up 53.24% from the prior year.
• Revenue for Q1 2026 stood at $1.7 million, down from $6.6 million in the prior quarter.
• The five-year high for Revenue was $6.6 million in Q4 2025, with the low at $1.2 million in Q3 2023.
• The 5-year median for Revenue is $2.8 million (2025), against an average of $2.9 million.
• Peak annual rise in Revenue reached 1239.39% in 2022, while the deepest fall reached 96.17% in 2022.
• Lineage Cell Therapeutics' Revenue stood at $1.9 million in 2022, then increased by 9.03% to $2.1 million in 2023, then surged by 37.36% to $2.9 million in 2024, then soared by 130.4% to $6.6 million in 2025, then slumped by 73.9% to $1.7 million in 2026.
• Business Quant data shows LCTX's Revenue at $1.7 million in Q1 2026, $6.6 million in Q4 2025, and $3.7 million in Q3 2025.